We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been recognized as an IAM Global Leader 2026. To qualify, individuals must first be ranked in the gold tier of the IAM Patent 1000. From that group, IAM chooses select individuals who merit special attention ”for their ability to innovate, inspire and go above and beyond to deliver value for their clients.”

IAM has published a longer Q&A article featuring Jennifer where she answers questions about her unique career path, advice to biopharma start-ups, latest “hot IP topics”, and her approach to patent portfolio strategy. Feel free to check it out!


Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

我們過去活動

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Recommended Insights

Markush claims in China - what can be arbitrarily deleted during invalidation?

2018年12月4日
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]
閱讀更多 >

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
閱讀更多 >

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

2022年6月30日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
閱讀更多 >

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

2024年1月25日
December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of […]
閱讀更多 >
Top crossarrow-right